BridgeBio takes crown for biggest biotech IPO of 2019, as fellow unicorn Adaptive raises offering size and price
BridgeBio Pharma and Adaptive Biotechnologies have not just upsized IPO offerings — the pair of unicorns have also raised their offering prices above the range, hauling in a combined $648.5 million.
Neil Kumar’s BridgeBio Pharma, founded in 2015, has a stable of companies focused on diseases that are driven by defects in a single gene — encompassing dermatology, cardiology, neurology, endocrinology, renal disease, and ophthalmology — and cancers with clear genetic drivers. The startup mill birthed a plethora of firms such as Eidos, Navire, QED Therapeutics and PellePharm, which function as its subsidiaries.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.